{
    "organizations": [],
    "uuid": "046499493be242eecc4a05b881568e1951adc8bc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vanda-pharmaceuticals-gets-paragra/brief-vanda-pharmaceuticals-gets-paragraph-iv-certification-notice-for-generic-version-of-hetlioz-capsule-idUSFWN1R80HD",
    "ord_in_thread": 0,
    "title": "BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE\n* VANDA SAYS IN LETTER, TEVA ALLEGES SOME PATENTS WILL NOT BE INFRINGED BY ITS USE OR SALE OF 20MG HETLIOZ - SEC FILING Source text ( bit.ly/2pFMoh0 ) Further company coverage:\n ",
    "published": "2018-03-26T19:56:00.000+03:00",
    "crawled": "2018-03-27T11:37:17.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "vanda",
        "pharmaceutical",
        "march",
        "got",
        "paragraph",
        "iv",
        "certification",
        "notice",
        "letter",
        "regarding",
        "anda",
        "teva",
        "generic",
        "version",
        "20mg",
        "hetlioz",
        "capsule",
        "vanda",
        "say",
        "letter",
        "teva",
        "alleges",
        "patent",
        "infringed",
        "use",
        "sale",
        "20mg",
        "hetlioz",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}